SL-052

CAT: 0804-HY-19873Size: 1 EachDry Ice: NoHazardous: No
CAT#:0804-HY-19873Size:1 Each
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
SL-052 is a hypocrellin-based photosensitizer that has recently shown promising results in clinical and preclinical testing for cancer photodynamic therapy (PDT) . SL-052 is encapsulated in biodegradable polylactic-co-glycolic acid (PLGA) polymer nanoparticles optimized using single emulsion solvent evaporation technology. The SL-052-PLGA nanoparticles were more effective in PDT treatment of subcutaneous SCCVII squamous cell carcinoma compared to polyvinylpyrrolidone (PVP) -based and standard liposomal SL-052 formulations. A longer time interval between drug injection and tumor illumination can improve tumor cure rates, and SL-052-PLGA nanoparticles showed the best therapeutic effect among all SL-052 formulations.
CAS Number
[925438-34-2]
UNSPSC
12352005
Target
Photosensitizer
Type
Reference compound
Related Pathways
Apoptosis
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/sl-052.html
Smiles
COC(C([C@H](C(C)=CC1=C(N[C@](CCCC2)([H])[C@@]2([H])N3)C3=C4C5=O)C(C)=O)=C6C1=C4C(C(OC)=C5)=C7C6=C8C(C=C7OC)=O)=C8O
Molecular Formula
C35H32N2O7
Molecular Weight
592.64
References & Citations
[1]Antitumor Efficacy of Photodynamic Therapy Using Novel Nanoformulations of Hypocrellin Photosensitizer SL052
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Popular Products